Cinnarizine: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: May 15, 2026

Cinnarizine

Antivertigo Preparations

GB MHRA

Drug class: Antivertigo Preparations
Availability: See label
Markets covered: 1
Products on record: 6

N07CAAntivertigo Preparations

Overview

Cinnarizine is an active pharmaceutical ingredient in the Antivertigo Preparations group (N07CA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	6	May 15, 2026

GBUnited Kingdom· MHRA

6 products

Uses

GBOfficial regulatory label· revised May 15, 2026[1]

Disorders of balance - maintenance therapy for symptoms of labyrinthine disorders, including vertigo, tinnitus, nystagmus, nausea and vomiting such as is seen in Meniere's Disease. Cinnarizine is also effective in the control of motion sickness.

How to take

Sources & citations

[1]MHRA (UK) · PL045690476 · revised May 15, 2026

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised May 15, 2026[1]

The safety of cinnarizine was evaluated in 303 cinnarizine-treated subjects who participated in 6 placebo-controlled trials for the indications peripheral circulatory disorders, cerebral circulatory disorders, vertigo and control of motion sickness ; and in 937 cinnarizine-treated subjects who participated in six comparator and 13 open label clinical trials for the indications peripheral circulatory disorders, cerebral circulatory disorders and vertigo.
5). Including the above mentioned ADRs, the following ADRs have been observed from clinical trials and post-marketing experiences reported with the use of cinnarizine.
Frequencies displayed use the following convention:
Very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from the available data). Adverse drug reactions Frequency category System organ class Common (≥ 1/100 to < 1/10) Uncommon (≥ 1/1,000 to < 1/100) Rare (≥ 1/10,000 to <1/1,000) Not known Nervous system disorders Somnolence Hypersomnia Dyskinesia, extrapyramidal disorder,, Parkinsonism, Tremor Gastrointestinal disorders Nausea, Vomiting Upper abdominal pain, Dyspepsia Hepatobiliary disorders Cholestatic jaundice Skin and subcutaneous tissue disorders Hyperhidrolysis, Lichenoid keratosis including lichen planus Subacute cutaneous lupus erythematosus Musculoskeletal and connective tissue disorders Muscle rigidity General disorders and administrative site conditions Fatigue Investigations Weight increased Cases of hypersensitivity, headache and dry mouth have also been reported.
Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA yellow card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised May 15, 2026[1]

As with other antihistamines, cinnarizine may cause epigastric discomfort; taking it after meals may diminish gastric irritation. Cinnarizine should only be given to patients with Parkinson's disease if the advantages outweigh the possible risk of aggravating this disease.
Because of its antihistamine effect, cinnarizine may prevent an otherwise positive reaction to dermal reactivity indicators if used within 4 days prior to testing. Use of cinnarizine should be avoided in porphyria. There have been no specific studies in hepatic or renal dysfunction.
Cinnarizine should be used with care in patients with hepatic or renal insufficiency. Cinnarizine Tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drugs in the same class

Sources & citations